Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-04-28 Investor Presentation
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于举行2018年度业绩网上说明会的通知
Investor Presentation Classification · 95% confidence The document is a notice about holding an online performance briefing for the 2018 annual results of 康芝药业股份有限公司. It mentions that the 2018 Annual Report has already been published on April 29, 2019, and the briefing is scheduled for May 10, 2019. The document invites investors to participate in the online meeting to understand the company's development strategy and operations. This is clearly an announcement of an investor presentation event related to the annual results, not the actual annual report or earnings release itself. Therefore, the document fits the category of Investor Presentation (IP). The document length is short and it is an announcement of a presentation event, not the presentation slides or detailed report itself, so it is not a Report Publication Announcement (RPA).
2019-04-28 Chinese
关于公司日常关联交易事项的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the company's daily related party transactions for the year 2019, including the approval process by the board of directors, expected transaction amounts, related parties involved, and independent directors' opinions. It includes voting results from the board meeting and detailed descriptions of the related parties and their financial status. The document is not a financial report like an annual or interim report, nor is it a simple announcement of a report publication. It is a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese listed companies. It does not fit into categories like MANG (management changes), ER (earnings release), or CAP (capital update). Given the nature and content, the best fitting category is Regulatory Filings (RNS). The document length (5798 characters) and detailed content support this classification with high confidence.
2019-04-28 Chinese
募集资金存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from an accounting firm (Mazars Certified Public Accountants LLP) providing an assurance opinion on the company's special report regarding the storage and actual use of raised funds for the fiscal year ending December 31, 2018. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The document includes detailed financial data on the amount raised, usage, balances, management agreements, and investment projects related to the raised funds. This is a specialized assurance report on the use of capital raised by the company, not a full annual report or earnings release. It is not a simple announcement or certification but a standalone audit/assurance report on a specific financial aspect (raised funds usage). Therefore, it fits best under the category 'Audit Report / Information (AR)' which covers standalone audit reports and applied accounting principles excluding full annual reports. FY 2018
2019-04-28 Chinese
2018年度业绩快报修正公告
Regulatory Filings Classification · 95% confidence The document is titled as a "2018 年度业绩快报修正公告" which translates to "2018 Annual Performance Quick Report Revision Announcement." It contains revised financial data for the 2018 fiscal year, including revenue, profit, and net income figures, and explanations for the revisions. The document explicitly states that the data is preliminary and subject to final audit in the annual report. It is a correction or revision announcement of previously released financial performance data, not the full annual report itself. The document length is 3371 characters, which is relatively short and consistent with an announcement rather than a full report. The text also includes a statement from the board apologizing for the revision and explaining the reasons, which is typical for a correction announcement. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an announcement of a revision to previously disclosed financial results and not the full annual report or a detailed financial report.
2019-04-24 Chinese
2019第一季度业绩预告
Regulatory Filings Classification · 95% confidence The document is a quarterly earnings forecast for the first quarter of 2019 by 康芝药业股份有限公司. It includes estimated net profit figures, explanations for performance changes, and a disclaimer that the forecast is unaudited and preliminary. The document length is short (1139 characters) and it does not contain actual financial statements or detailed financial data, only projections and explanations. It is not a full interim report (IR) because it lacks substantive financial data and is explicitly a forecast. It is not an earnings release (ER) because it is a forecast, not an announcement of actual results. The document is a regulatory announcement of expected quarterly performance, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other categories.
2019-04-09 Chinese
关于全资子公司获得高新技术企业认证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from 康芝药业股份有限公司 about its wholly-owned subsidiary receiving a High-Tech Enterprise Certification, which includes information about tax benefits and the positive impact on the company. It is a regulatory announcement about a certification and does not contain financial statements, management discussion, or detailed report content. The document length is only 621 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit other specific categories.
2019-03-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.